Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Jeffrey Sum Lung WongGerry Gin Wai KwokVikki TangBryan Cho Wing LiRoland LeungJoanne ChiuKa Wing MaWong Hoi SheJosephine TsangChung Mau LoTan To CheungThomas YauPublished in: Journal for immunotherapy of cancer (2022)
Ipilimumab and nivolumab/pembrolizumab can achieve durable antitumor activity and encouraging survival outcomes with acceptable toxicity in patients with advanced HCC who had prior treatment with ICIs.